ABVC BioPharma, Inc. (ABVC)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | -796K | 0.00 |
| Gross Profit | 0.00 | 0.00 | -796K | 0.00 |
| Operating Income | -2.3M | -2.0M | -3.0M | -1.6M |
| Net Income | -2.3M | -2.0M | -3.6M | -1.6M |
| Diluted EPS | $-0.13 | $-0.09 | $nan | $-0.06 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 970K | 152K | 510K | 0.00 |
| Gross Profit | 683K | -150K | 509K | 0.00 |
| Operating Income | -15.1M | -6.8M | -4.7M | -7.2M |
| Net Income | -16.4M | -7.8M | -4.9M | -7.9M |
| Diluted EPS | $-5.20 | $-1.80 | $-0.42 | $-0.39 |